Nuclear Medicine and Applications for Diagnosis and Treatment
Nuclear medicine is a specialty that covers the medical applications carried out using radioactive substances in the diagnosis, monitoring and, in some cases, treatment processes of diseases. The assessments made in this field aim to provide additional information about the functional state of organs and tissues. Nuclear medicine applications hold an important place particularly in processes such as cancer diagnosis, evaluating the spread of the disease and monitoring the response to treatment.
Unlike conventional imaging techniques, nuclear medicine methods allow the evaluation not only of anatomical structure but also of cellular and metabolic activities. In this way, more detailed information about the functional state of tissues can be obtained. This feature makes nuclear medicine an approach that is preferred particularly in oncological assessments.
Nuclear medicine applications are addressed at the diagnosis stage, before treatment planning or in the monitoring of the treatment process, in line with clinical requirements. These methods are addressed not as an assessment tool on their own, but together with other diagnostic and imaging methods, as a complementary part of the oncological assessment process. The aim is to contribute to the evaluation of the patient’s clinical data from a more holistic perspective.
What Is Nuclear Medicine ?
The question what is nuclear medicine? is one of the topics frequently researched by patients and their relatives seeking information about diagnosis and treatment processes. Nuclear medicine is a field of medicine that aims to evaluate the functional state of organs and tissues through radioactive substances given to the body in very low doses. These applications allow the examination not only of the structural but also of the functional and metabolic characteristics of organs.
Nuclear medicine methods offer a different perspective from conventional imaging techniques. While methods such as computed tomography (CT) or magnetic resonance (MR) mostly show anatomical structure, nuclear medicine applications aim to provide information about the biological activities of tissues. In this respect, nuclear medicine takes on a supporting role particularly in the early-stage evaluation and monitoring processes of diseases.
Nuclear medicine applications may be evaluated in different clinical fields, primarily in oncological diseases. However, these methods are not applied routinely for every patient. In which situations a nuclear medicine examination is necessary is determined in line with the patient’s clinical findings and the data obtained from other diagnostic methods. This approach ensures that nuclear medicine is evaluated in a controlled and purpose-focused manner.
Diagnosis and Monitoring Approaches in Nuclear Medicine
Diagnosis and monitoring in nuclear medicine covers the approaches that allow functional and metabolic data to be obtained in the evaluation of diseases. These methods may be evaluated to provide additional information about the extent of the disease during the diagnosis process and to monitor changes that may occur during the treatment process.
In particular, nuclear medicine in cancer takes on a supporting role in processes such as evaluating the stage of the disease, examining suspicious areas and monitoring the response to treatment. Nuclear medicine examinations are addressed at the pre-treatment planning stage or during the post-treatment monitoring process, in line with clinical requirements.
Nuclear medicine applications for diagnosis and monitoring do not have the aim of making a definitive diagnosis on their own. The data obtained from these methods is evaluated together with clinical examination, pathology results and other imaging methods. This holistic approach contributes to a sounder interpretation of the patient’s clinical data.
Monitoring approaches in nuclear medicine aim to provide information about the course of the disease at certain stages of the treatment process. The findings obtained in this process may offer a supporting framework for reviewing the treatment plan.
PET-CT Imaging Method
PET-CT is one of the imaging methods frequently used in the field of nuclear medicine and holding an important place in diagnosis and monitoring processes. This method allows positron emission tomography (PET), which shows metabolic activity, and computed tomography (CT), which reveals anatomical structure, to be evaluated together. In this way, both the structural and functional characteristics of tissues can be examined at the same time.
PET-CT may be addressed particularly in oncological assessments, for the purpose of examining the spread of the disease and providing additional information regarding the treatment process. The decision to apply it is made in line with clinical requirements and by taking the patient’s data into account.
What Is PET-CT ?
The question what is PET-CT? is among the topics most frequently researched by users seeking information about nuclear medicine applications. PET-CT is a method in which PET imaging, which shows the metabolic activity of cells, and CT imaging, which provides anatomical detail, are combined within a single examination.
Thanks to this method, metabolically active areas can be evaluated more clearly. The images obtained are addressed together with other diagnostic methods during the clinical assessment process.
Why Is a PET-CT Scan Performed ?
The question why is a PET-CT scan performed? is generally related to diagnosis and monitoring processes. PET-CT may be requested for the purpose of evaluating the spread of the disease, examining suspicious areas and obtaining additional data regarding the treatment process.
This imaging method may be evaluated at the diagnosis stage as well as before treatment planning or during the post-treatment monitoring process, in line with clinical requirements. It is not a routine application for every patient.
When Is PET-CT Evaluated in Cancer ?
PET-CT in cancer may be addressed during the diagnosis process, before treatment planning or at the post-treatment monitoring stage. At which stage a PET-CT scan is appropriate is determined in line with the type of cancer, its clinical course and the patient’s other medical data.
PET-CT applications do not have the aim of making a definitive diagnosis on their own. The findings obtained are interpreted together with other examinations as part of the clinical assessment process. This approach contributes to the diagnosis and monitoring process being addressed in a more balanced and controlled manner.
Ga-68 PSMA and PSMA PET-CT Applications
Ga-68 PSMA and PSMA PET-CT are among the special imaging methods used in the field of nuclear medicine, particularly in prostate cancer assessments. These applications cover assessments made by targeting PSMA (Prostate-Specific Membrane Antigen), which may be found at high levels in prostate cancer cells.
PSMA PET-CT may be addressed for the purpose of examining the spread of the disease, evaluating suspicious foci and obtaining additional information regarding the monitoring process. This method is evaluated as complementary to the information obtained through conventional imaging methods.
What Is Ga-68 PSMA ?
The question what is Ga-68 PSMA? is frequently researched by patients in the prostate cancer diagnosis or monitoring process. Ga-68 PSMA refers to the nuclear medicine imaging application carried out using a PSMA-targeted radioactive tracer.
Thanks to this application, the metabolic activity of tissues showing PSMA expression can be evaluated. However, the Ga-68 PSMA examination is not applied routinely for every patient and is addressed only in clinical situations deemed suitable.
In Which Situations Is PSMA PET-CT Evaluated ?
PSMA PET-CT may be evaluated during the diagnosis process, before treatment planning or at the post-treatment monitoring stage, in line with clinical requirements. In which patients the PSMA PET-CT application is appropriate is determined in the light of the patient’s clinical data and scientific assessments.
This imaging method is not evaluated as a diagnostic procedure on its own. The findings obtained are interpreted together with clinical examination, pathology results and other imaging methods. This approach contributes to the assessment process progressing in a sounder and more controlled manner.
Radionuclide Treatments and Lutetium (Lu-177) Applications
Radionuclide treatments cover the treatment approaches in which substances carrying radioactive properties are used in a targeted manner, and which may be evaluated in certain diseases within the field of nuclear medicine. Unlike nuclear medicine methods for diagnostic purposes, these applications involve assessments aimed at the treatment process.
Radionuclide treatments are not a standard method for every patient. In which patients and under which conditions these treatments are addressed is determined at the end of a detailed clinical assessment process. Decisions regarding treatment are evaluated in line with the patient’s medical data and scientific guidelines.
What Is Lutetium (Lu-177) Treatment ?
Lutetium treatment (Lu-177) is an application that is among the radionuclide treatment approaches and that is evaluated only in patient groups deemed suitable. In this method, the Lu-177 substance, which carries radioactive properties, is used in line with certain targets.
Lu-177 treatment is not a method that can be applied in every cancer type and in every patient. The decision to apply it is made by taking into account the characteristics of the disease, previous treatment processes and the patient’s general health condition. For this reason, the treatment process is planned specifically for the patient.
In Whom Is Lu-177 Treatment Evaluated ?
The question to whom is Lu-177 treatment applied? is frequently researched by users seeking information about radionuclide treatments. This treatment approach is evaluated only under certain clinical conditions and in patient groups deemed suitable.
The assessments made before treatment cover addressing the patient’s clinical data in a holistic manner. In the post-application process, importance is given to patient monitoring and information. Lu-177 treatment is addressed as part of the nuclear medicine and oncology assessment process.
The Clinical Assessment Process in Nuclear Medicine Applications
The clinical assessment process in nuclear medicine applications covers addressing the patient’s medical information in a holistic manner. In this process, clinical findings, data regarding the diagnosis process, previous imaging results and the current treatment plan are evaluated together. The aim is to determine, specifically for the patient, at which stage and within which scope nuclear medicine applications are addressed.
Nuclear medicine examinations and treatment-oriented applications are not evaluated as decision-making methods on their own. The findings obtained are interpreted together with clinical examination, pathology results and other imaging methods. This approach contributes to the diagnosis and monitoring process progressing in a more balanced and controlled manner.
In the oncological assessments carried out by Dr. Hasan Morcalı, nuclear medicine applications are addressed as a complementary part of the diagnosis, monitoring and treatment process. During the clinical assessment process, patient information and monitoring are kept at the forefront; the applications are evaluated in line with scientific and ethical principles.
👉 You can get in touch for general information about the assessment process regarding nuclear medicine applications, PET-CT, PSMA PET-CT or radionuclide treatments.
Our Working Hours
- 10:00-17:00
- 10:00-17:00
- 10:00-17:00
- 10:00-17:00
- 10:00-17:00
- 10:00-18:00
Frequently Asked Questions (FAQ)
In which diseases is nuclear medicine evaluated? Nuclear medicine applications may be evaluated in the diagnosis and monitoring processes of different diseases, primarily cancer. In which situations a nuclear medicine examination is appropriate is determined in line with clinical requirements.
Why is a PET-CT scan performed? PET-CT may be requested for the purpose of evaluating the spread of the disease, examining suspicious areas and obtaining additional information regarding the treatment process. A PET-CT scan is not routine for every patient and is evaluated in line with clinical requirements.
When is PET-CT evaluated in cancer? PET-CT in cancer may be evaluated at the diagnosis stage, before treatment planning or during the post-treatment monitoring process. At which stage it is performed is determined by taking into account the type of disease and its clinical course.
What are Ga-68 PSMA and PSMA PET-CT? Ga-68 PSMA and PSMA PET-CT are nuclear medicine imaging methods used particularly in prostate cancer assessments. These applications are evaluated only in clinical situations deemed suitable.
To whom is Lu-177 treatment applied? Lu-177 treatment is evaluated only under clinical conditions deemed suitable and in certain patient groups. The decision to apply it is made at the end of a detailed clinical assessment process.
Are nuclear medicine applications safe? The radioactive substances used in nuclear medicine applications are applied within determined doses and under controlled conditions. Clinical assessment and information in the pre- and post-application process are important.
Do nuclear medicine examinations make a diagnosis on their own? No. Nuclear medicine examinations are not used for the purpose of making a definitive diagnosis on their own. The findings obtained are evaluated together with clinical examination, pathology results and other imaging methods.
How does Dr. Hasan Morcalı evaluate nuclear medicine applications? Dr. Hasan Morcalı addresses nuclear medicine applications as a complementary part of the diagnosis, monitoring and treatment process. Assessments are made in line with scientific and ethical principles; patient information is an important part of the process.
How can information be obtained for a nuclear medicine assessment? Patients who would like to get general information about the assessment process regarding nuclear medicine applications, PET-CT, PSMA PET-CT or radionuclide treatments can get in touch with the clinic of Dr. Hasan Morcalı.
The information on this site is not intended for diagnosis or treatment. Please consult your physician for your health problems.
